Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer

The incidence of colorectal cancer (CRC) has increased. CRC is the third most common cancer and the fourth most common cause of cancer-related deaths in Korea. Palliative chemotherapy can be used to shrink tumors and ease symptoms caused by the cancer when cure is not possible. It is important to id...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Sun Kyung, Lee, Kyu Taek, Bae, Sang Byung, Lee, Sang-Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823574/
https://www.ncbi.nlm.nih.gov/pubmed/31346151
http://dx.doi.org/10.3904/kjim.2019.071
Descripción
Sumario:The incidence of colorectal cancer (CRC) has increased. CRC is the third most common cancer and the fourth most common cause of cancer-related deaths in Korea. Palliative chemotherapy can be used to shrink tumors and ease symptoms caused by the cancer when cure is not possible. It is important to identify chemotherapeutic agents that can be used to effectively treat metastatic CRC (mCRC) and thus improve the survival and quality of life of patients with mCRC. This review aimed to evaluate the recent developments in palliative chemotherapy for mCRC and the biological or targeted agents used based on genetic alterations.

Ejemplares similares